Sanctuary Advisors LLC Takes $89,000 Position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)

Sanctuary Advisors LLC purchased a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) during the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm purchased 13,498 shares of the company’s stock, valued at approximately $89,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Charles Schwab Investment Management Inc. boosted its holdings in shares of Recursion Pharmaceuticals by 17.5% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,940,680 shares of the company’s stock valued at $12,789,000 after acquiring an additional 288,926 shares during the period. FMR LLC lifted its position in Recursion Pharmaceuticals by 2.1% in the 3rd quarter. FMR LLC now owns 8,363,530 shares of the company’s stock valued at $55,116,000 after purchasing an additional 170,810 shares during the last quarter. State Street Corp boosted its stake in Recursion Pharmaceuticals by 47.1% during the 3rd quarter. State Street Corp now owns 12,870,272 shares of the company’s stock valued at $84,815,000 after purchasing an additional 4,120,685 shares during the period. Geode Capital Management LLC grew its position in Recursion Pharmaceuticals by 13.7% in the 3rd quarter. Geode Capital Management LLC now owns 5,431,911 shares of the company’s stock worth $35,803,000 after purchasing an additional 656,003 shares during the last quarter. Finally, Perceptive Advisors LLC acquired a new stake in shares of Recursion Pharmaceuticals in the second quarter valued at approximately $5,769,000. Institutional investors and hedge funds own 89.06% of the company’s stock.

Recursion Pharmaceuticals Trading Down 8.4 %

Shares of RXRX stock opened at $6.77 on Tuesday. The company has a quick ratio of 4.35, a current ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock has a 50-day simple moving average of $6.81 and a 200 day simple moving average of $7.13. Recursion Pharmaceuticals, Inc. has a fifty-two week low of $5.60 and a fifty-two week high of $15.74. The stock has a market capitalization of $1.94 billion, a P/E ratio of -4.42 and a beta of 0.85.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.34) earnings per share for the quarter, missing the consensus estimate of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The business had revenue of $26.08 million for the quarter, compared to the consensus estimate of $12.62 million. During the same quarter last year, the business posted ($0.43) EPS. The business’s revenue for the quarter was up 147.6% on a year-over-year basis. On average, sell-side analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Christopher Gibson sold 20,000 shares of Recursion Pharmaceuticals stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $6.16, for a total value of $123,200.00. Following the transaction, the chief executive officer now directly owns 762,656 shares of the company’s stock, valued at $4,697,960.96. This trade represents a 2.56 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, CFO Michael Secora sold 15,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the completion of the sale, the chief financial officer now owns 1,499,631 shares of the company’s stock, valued at approximately $11,487,173.46. This trade represents a 0.99 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 90,341 shares of company stock worth $611,490. 15.75% of the stock is owned by insiders.

Analysts Set New Price Targets

RXRX has been the subject of a number of recent analyst reports. Leerink Partners decreased their price objective on Recursion Pharmaceuticals from $9.00 to $8.00 and set a “market perform” rating for the company in a report on Tuesday, September 3rd. Jefferies Financial Group lowered their price target on Recursion Pharmaceuticals from $8.00 to $6.00 and set a “hold” rating on the stock in a report on Tuesday, September 3rd. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a report on Wednesday, December 11th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to data from MarketBeat, Recursion Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $9.25.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.